{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:33:33Z","timestamp":1790087613937,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Type 2 diabetes (T2DM) is associated with aggregation of the human islet amyloid polypeptide (hIAPP) into cytotoxic amyloid species. Here we tested the effect of a diphenylpyrazole (DPP)-derived small molecule inhibitor, anle145c, on cytotoxicity and on aggregation properties of hIAPP. We demonstrate that incubation of hIAPP with the inhibitor yields ~10 nm-sized non-toxic oligomers, independent of the initial aggregation state of hIAPP. This suggests that anle145c has a special mode of action in which anle145c-stabilized oligomers act as a thermodynamic sink for the preferred aggregation state of hIAPP and anle145c. We also demonstrate that the inhibitor acts in a very efficient manner, with sub-stoichiometric concentrations of anle145c being sufficient to (i) inhibit hIAPP-induced death of INS-1E cells, (ii) prevent hIAPP fibril formation in solution, and (iii) convert preformed hIAPP fibrils into non-toxic oligomers. Together, these results indicate that anle145c is a promising candidate for inhibition of amyloid formation in T2DM.<\/jats:p>","DOI":"10.1038\/s41598-019-54919-z","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T11:04:00Z","timestamp":1576235040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers"],"prefix":"10.1038","volume":"9","author":[{"given":"Manikam S.","family":"Saravanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Ryazanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Leonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrique","family":"Praest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Khemtemourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antoinette","family":"Killian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"54919_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","volume":"75","author":"F Chiti","year":"2006","unstructured":"Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem 75, 333\u2013366 (2006).","journal-title":"Annu. Rev. Biochem"},{"key":"54919_CR2","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","volume":"148","author":"D Eisenberg","year":"2012","unstructured":"Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188\u20131203 (2012).","journal-title":"Cell"},{"key":"54919_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2015.04.005","volume":"21","author":"A Mukherjee","year":"2015","unstructured":"Mukherjee, A., Morales-Scheihing, D., Butler, P. C. & Soto, C. Type 2 Diabetes as a Protein Misfolding Disease. Trends Mol. Med. 21, 439\u2013449 (2015).","journal-title":"Trends Mol. Med."},{"key":"54919_CR4","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1039\/C7CS00372B","volume":"46","author":"PC Ke","year":"2017","unstructured":"Ke, P. C. et al. Implications of peptide assemblies in amyloid diseases. Chem. Soc. Rev. 46, 6492\u20136531 (2017).","journal-title":"Chem. Soc. Rev."},{"key":"54919_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJM200008103430607","volume":"343","author":"JWM H\u00f6ppener","year":"2000","unstructured":"H\u00f6ppener, J. W. M., Ahr\u00e9n, B. & Lips, C. J. M. Islet amyloid and type 2 diabetes mellitus. NEJM 343, 411\u2013419 (2000).","journal-title":"NEJM"},{"key":"54919_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrendo.2016.169","volume":"3","author":"PJ Meikle","year":"2017","unstructured":"Meikle, P. J. & Summers, S. A. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat. Rev. Endocrinol 3, 79\u201391 (2017).","journal-title":"Nat. Rev. Endocrinol"},{"key":"54919_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrendo.2011.183","volume":"8","author":"L Chen","year":"2012","unstructured":"Chen, L., Magliano, D. J. & Zimmet, P. Z. The worldwide epidemiology of type 2 diabetes mellitus \u2013 present and future perspectives. Nat. Rev. Endocrinol 8, 228\u2013236 (2012).","journal-title":"Nat. Rev. Endocrinol"},{"key":"54919_CR8","doi-asserted-by":"publisher","unstructured":"Pulgaron, E. R. & Delamater, A. M. Obesity and Type 2 Diabetes in Children: Epidemiology and Treatment Curr. Diabetes Rep, https:\/\/doi.org\/10.1007\/s11892-014-0508-y (2014).","DOI":"10.1007\/s11892-014-0508-y"},{"key":"54919_CR9","first-page":"235","volume":"9","author":"OR Temneanu","year":"2016","unstructured":"Temneanu, O. R., Trandafir, L. M. & Purcarea, M. R. Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J. Med. Life 9, 235\u2013239 (2016).","journal-title":"J. Med. Life"},{"key":"54919_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.suc.2011.08.001","volume":"91","author":"H Shamseddeen","year":"2011","unstructured":"Shamseddeen, H., Getty, J. Z., Hamdallah, I. N. & Ali, M. R. Epidemiology and Economic Impact of Obesity and Type 2 Diabetes. Surg. Clin. North Am. 91, 1163\u20131172 (2011).","journal-title":"Surg. Clin. North Am."},{"key":"54919_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1152\/physrev.00042.2009","volume":"91","author":"P Westermark","year":"2011","unstructured":"Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795\u2013826 (2011).","journal-title":"Physiol. Rev."},{"key":"54919_CR12","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","volume":"84","author":"GJ Cooper","year":"1997","unstructured":"Cooper, G. J. et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA 84, 8628\u20138632 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"54919_CR13","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","volume":"84","author":"P Westermark","year":"1997","unstructured":"Westermark, P. et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Nat. Acad. Sci. USA 84, 3881\u20133885 (1997).","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"54919_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0140-6736(87)90825-7","volume":"2","author":"A Clark","year":"1987","unstructured":"Clark, A. et al. Islet amyloid formed from diabetes-associated peptide may be a pathogenic in type 2-diabetes. Lancet 2, 231\u2013234 (1987).","journal-title":"Lancet"},{"key":"54919_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/368756a0","volume":"368","author":"A Lorenzo","year":"1994","unstructured":"Lorenzo, A., Razzaboni, B., Weir, G. C. & Yankner, B. A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756\u2013760 (1994).","journal-title":"Nature"},{"key":"54919_CR16","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1039\/C4MT00130C","volume":"10","author":"A Sinopoli","year":"2014","unstructured":"Sinopoli, A. et al. The role of copper(II) in the aggregation of human amylin. Metallomics 10, 1841\u20131852 (2014).","journal-title":"Metallomics"},{"key":"54919_CR17","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.bbamem.2018.02.022","volume":"1860","author":"MFM Sciacca","year":"2018","unstructured":"Sciacca, M. F. M., Tempra, C., Scollo, F., Milardi, D. & La Rosa., C. Amyloid growth and membrane damage: Current themes and emerging perspectives from theory and experiments on A\u03b2 and hIAPP. Biochim. Biophys. Acta. 1860, 1625\u20131638 (2018).","journal-title":"Biochim. Biophys. Acta."},{"key":"54919_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0014-5793(95)01512-4","volume":"379","author":"P Westermark","year":"1996","unstructured":"Westermark, P., Li, Z. C., Westermark, G. T., Leckstr\u00f6m, A. & Steiner, D. F. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 379, 203\u2013206 (1996).","journal-title":"FEBS Lett."},{"key":"54919_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jmb.2003.10.045","volume":"335","author":"JL Larson","year":"2004","unstructured":"Larson, J. L. & Miranker, A. D. The Mechanism of Insulin Action on Islet Amyloid Polypeptide Fiber Formation. J. Mol. Biol. 335, 221\u2013231 (2004).","journal-title":"J. Mol. Biol."},{"key":"54919_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1042\/bj20030852","volume":"377","author":"ETAS Jaikaran","year":"2004","unstructured":"Jaikaran, E. T. A. S., Nilsson, M. R. & Clark, A. Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem. J. 377, 709\u2013716 (2004).","journal-title":"Biochem. J."},{"key":"54919_CR21","doi-asserted-by":"publisher","first-page":"12912","DOI":"10.1021\/ja504031d","volume":"37","author":"AC Susa","year":"2014","unstructured":"Susa, A. C. et al. Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions. J. Am. Chem. Soc. 37, 12912\u201312919 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"54919_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jmb.2012.11.003","volume":"425","author":"H Wang","year":"2012","unstructured":"Wang, H., Cao, P. & Raleigh, D. P. Amyloid Formation in Heterogeneous Environments: Islet Amyloid Polypeptide Glycosaminoglycan Interactions. J. Mol. Biol. 425, 492\u2013505 (2012).","journal-title":"J. Mol. Biol."},{"key":"54919_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1139\/bcb-2016-0236","volume":"95","author":"N Quittot","year":"2017","unstructured":"Quittot, N., Sebastiao, M. & Bourgault, S. Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance. Biochem Cell Biol. 95, 329\u2013337 (2017).","journal-title":"Biochem Cell Biol."},{"key":"54919_CR24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.bbamem.2010.05.022","volume":"1798","author":"L Khemt\u00e9mourian","year":"2010","unstructured":"Khemt\u00e9mourian, L., Engel, M. F. M., Liskamp, R. M. J., H\u00f6ppener, J. W. M. & Killian, J. A. The N-terminal fragment of human islet amyloid polypeptide is non-fibrillogenic in the presence of membranes and does not cause leakage of bilayers of physiologically relevant lipid composition. Biochim. Biophys. Acta 1798, 1805\u20131811 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"54919_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5639875","volume":"2016","author":"L Caillon","year":"2016","unstructured":"Caillon, L., Hoffmann, A. R. F., Botz, A. & Khemtemourian, L. Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus. J. Diabetes Res. 2016, 1\u201313 (2016).","journal-title":"J. Diabetes Res."},{"key":"54919_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","volume":"52","author":"AE Butler","year":"2003","unstructured":"Butler, A. E. et al. \u03b2-Cell Deficit and Increased \u03b2-Cell Apoptosis in Humans with Type 2 Diabetes. Diabetes 52, 102\u2013110 (2003).","journal-title":"Diabetes"},{"key":"54919_CR27","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P., Engstr\u00f6m, U., Johnson, K. H., Westermark, G. T. & Betsholtz, C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87, 5036\u20135040 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"54919_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2798269","volume":"2016","author":"Rehana Akter","year":"2016","unstructured":"Akter, R. et al. Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology. J. Diabetes Res. 2016, https:\/\/doi.org\/10.1155\/2016\/2798269","journal-title":"Journal of Diabetes Research"},{"key":"54919_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ilar.47.3.225","volume":"47","author":"AV Matveyenko","year":"2006","unstructured":"Matveyenko, A. V. & Butler, P. C. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR journal 47, 225\u2013233 (2006).","journal-title":"ILAR journal"},{"key":"54919_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2046327","volume":"2016","author":"Amit Pithadia","year":"2016","unstructured":"Pithadia, A., Brender, J. R., Fierke, C. A. & Ramamoorthy, A. Inhibition of IAPP aggregation and toxicity by natural producs and derivatives. J. Diabetes Res, https:\/\/doi.org\/10.1155\/2016\/2046327 (2016).","journal-title":"Journal of Diabetes Research"},{"key":"54919_CR31","doi-asserted-by":"publisher","first-page":"13147","DOI":"10.1021\/jf201702h","volume":"59","author":"B Cheng","year":"2011","unstructured":"Cheng, B. et al. Coffee Components Inhibit Amyloid Formation of Human Islet Amyloid Polypeptide in Vitro: Possible Link between Coffee Consumption and Diabetes Mellitus. J. Agric. Food Chem. 59, 13147\u201313155 (2011).","journal-title":"J. Agric. Food Chem."},{"key":"54919_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/anie.200901694","volume":"49","author":"I Saraogi","year":"2010","unstructured":"Saraogi, I. et al. Synthetic \u03b1-Helix Mimetics as Agonists and Antagonists of IAPP Amyloid Formation. Angew. Chem. Int. Ed. 49, 736\u2013739 (2010).","journal-title":"Angew. Chem. Int. Ed."},{"key":"54919_CR33","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1002\/anie.200705372","volume":"47","author":"R Mishra","year":"2008","unstructured":"Mishra, R. et al. Small-Molecule Inhibitors of Islet Amyloid Polypeptide Fibril Formation. Angew. Chem. Int. Ed. 47, 4679\u20134682 (2008).","journal-title":"Angew. Chem. Int. Ed."},{"key":"54919_CR34","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1073\/pnas.0507471103","volume":"103","author":"L-M Yan","year":"2006","unstructured":"Yan, L.-M., Tatarek-Nossol, M., Velkova, A., Kazantzis, A. & Kapurniotu, A. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. 103, 2046\u20132051 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"54919_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/13506129.2010.530008","volume":"17","author":"M Daval","year":"2010","unstructured":"Daval, M. et al. The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity. Amyloid 17, 118\u2013128 (2010).","journal-title":"Amyloid"},{"key":"54919_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.bioorg.2018.11.039","volume":"84","author":"SUB Farrukh","year":"2019","unstructured":"Farrukh, S. U. B. et al. Synthesis and identification of novel pyridazinylpyrazolone based diazocompounds as inhibitors of human islet amyloid polypeptide aggregation. Bioorg. Chem. 84, 339\u2013346 (2019).","journal-title":"Bioorg. Chem."},{"key":"54919_CR37","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1039\/c3cc41452c","volume":"49","author":"S Kumar","year":"2013","unstructured":"Kumar, S. & Miranker, A. D. A foldamer approach to targeting membrane bound helical states of islet amyloid polypeptide. Chem. Comm. 49, 4749 (2013).","journal-title":"Chem. Comm."},{"key":"54919_CR38","doi-asserted-by":"publisher","first-page":"20160127","DOI":"10.1098\/rsfs.2016.0127","volume":"7","author":"I Obasse","year":"2017","unstructured":"Obasse, I., Taylor, M., Fullwood, N. J. & Allsop, D. Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes. Interface Focus 7, 20160127 (2017).","journal-title":"Interface Focus"},{"key":"54919_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1039\/C7TB02538F","volume":"6","author":"B Ren","year":"2018","unstructured":"Ren, B. et al. Tanshinones Inhibit hIAPP Aggregation, Disaggregate Preformed hIAPP Fibrils, and Protect Cultured. Cells. J. Mater. Chem. B 6, 56\u201367 (2018).","journal-title":"Cells. J. Mater. Chem. B"},{"key":"54919_CR40","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 125, 795\u2013813 (2013).","journal-title":"Acta Neuropathol."},{"key":"54919_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","volume":"130","author":"J Wagner","year":"2015","unstructured":"Wagner, J. et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 130, 619\u2013631 (2015).","journal-title":"Acta Neuropathol."},{"key":"54919_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","volume":"127","author":"J Levin","year":"2014","unstructured":"Levin, J. et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 127, 779\u2013780 (2014).","journal-title":"Acta Neuropathol."},{"key":"54919_CR43","doi-asserted-by":"publisher","unstructured":"Fellner, L. et al. Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced Multiple System Atrophy. Front. Neurosci. 10, https:\/\/doi.org\/10.3389\/fnins.2016.00099 (2016).","DOI":"10.3389\/fnins.2016.00099"},{"key":"54919_CR44","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.bbagen.2015.05.021","volume":"1850","author":"AA Deeg","year":"2015","unstructured":"Deeg, A. A. et al. Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to \u03b1-synuclein aggregates. Biochim. Biophys. Acta - General Subjects 1850, 1884\u20131890 (2015).","journal-title":"Biochim. Biophys. Acta - General Subjects"},{"key":"54919_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.15252\/emmm.201707825","volume":"10","author":"A Martinez Hernandez","year":"2018","unstructured":"Martinez Hernandez, A. et al. The diphenylpyrazole compound anle138b blocks A\u03b2 channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine 10, 32\u201347 (2018).","journal-title":"EMBO Molecular Medicine"},{"issue":"4","key":"54919_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","volume":"138","author":"Michal Wegrzynowicz","year":"2019","unstructured":"Wegrzynowicz, M. et al. Depopulation of \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model. Acta Neuropathol, https:\/\/doi.org\/10.1007\/s00401-019-02023-x (2019).","journal-title":"Acta Neuropathologica"},{"key":"54919_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2019","unstructured":"Heras-Garvin, A. et al. Anle138b Modulates \u03b1-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy. Movement Disorders 34, 255\u2013263 (2019).","journal-title":"Movement Disorders"},{"key":"54919_CR48","doi-asserted-by":"publisher","unstructured":"Abedini, A. et al. Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics. eLife 5, https:\/\/doi.org\/10.7554\/eLife.12977 (2016).","DOI":"10.7554\/eLife.12977"},{"key":"54919_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0076-6879(99)09020-5","volume":"309","author":"H LeVine","year":"1999","unstructured":"LeVine, H. Quantification of \u03b2-Sheet Amyloid Fibril Structures with Thioflavin T. Meth. Enzymol. 309, 274\u2013284 (1999).","journal-title":"Meth. Enzymol."},{"key":"54919_CR50","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1021\/bi702518m","volume":"47","author":"F Meng","year":"2008","unstructured":"Meng, F., Marek, P., Potter, K. J., Verchere, C. B. & Raleigh, D. P. Rifampicin Does Not Prevent Amyloid Fibril Formation by Human Islet Amyloid Polypeptide but Does Inhibit Fibril Thioflavin-T Interactions: Implications for Mechanistic Studies of \u03b2-Cell Death. Biochemistry 47, 6016\u20136024 (2008).","journal-title":"Biochemistry"},{"key":"54919_CR51","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1039\/C7CP07516B","volume":"20","author":"ARF Hoffmann","year":"2018","unstructured":"Hoffmann, A. R. F. et al. Time dependence of NMR observables reveals salient differences in the accumulation of early aggregated species between human islet amyloid polypeptide and amyloid-\u03b2. Phys. Chem. Chem. Phys. 20, 9561\u20139573 (2018).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"54919_CR52","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1074\/jbc.M115.699348","volume":"291","author":"R Crespo","year":"2016","unstructured":"Crespo, R. et al. What Can the Kinetics of Amyloid Fibril Formation Tell about Off-pathway Aggregation? J. Biol. Chem. 291, 2018\u20132032 (2016).","journal-title":"J. Biol. Chem."},{"key":"54919_CR53","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1021\/bi0160462","volume":"41","author":"SB Padrick","year":"2002","unstructured":"Padrick, S. B. & Miranker, A. D. Islet Amyloid: Phase Partitioning and Secondary Nucleation Are Central to the Mechanism of Fibrillogenesis. Biochemistry 41, 4694\u20134703 (2002).","journal-title":"Biochemistry"},{"key":"54919_CR54","doi-asserted-by":"publisher","first-page":"16748","DOI":"10.1021\/jacs.7b08830","volume":"139","author":"AL Serrano","year":"2017","unstructured":"Serrano, A. L., Lomont, J. P., Tu, L.-H., Raleigh, D. P. & Zanni, M. T. A Free Energy Barrier Caused by the Refolding of an Oligomeric Intermediate Controls the Lag Time of Amyloid Formation by hIAPP. J. Am. Chem. Soc. 139, 16748\u201316758 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"54919_CR55","doi-asserted-by":"publisher","first-page":"19285","DOI":"10.1073\/pnas.1314481110","volume":"110","author":"LE Buchanan","year":"2013","unstructured":"Buchanan, L. E. et al. Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient \u03b2-sheet. Proc. Natl. Acad.Sci. USA 110, 19285\u201319290 (2013).","journal-title":"Proc. Natl. Acad.Sci. USA"},{"key":"54919_CR56","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1074\/jbc.M110.166678","volume":"286","author":"L Wei","year":"2011","unstructured":"Wei, L. et al. The Molecular Basis of Distinct Aggregation Pathways of Islet Amyloid Polypeptide. J. Biol. Chem. 286, 6291\u20136300 (2011).","journal-title":"J. Biol. Chem."},{"key":"54919_CR57","doi-asserted-by":"publisher","first-page":"E1994","DOI":"10.1073\/pnas.1421204112","volume":"112","author":"SW Chen","year":"2015","unstructured":"Chen, S. W. et al. Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation. Proc. Natl. Acad.Sci. USA 112, E1994\u2013E2003 (2015).","journal-title":"Proc. Natl. Acad.Sci. USA"},{"key":"54919_CR58","doi-asserted-by":"publisher","first-page":"14503","DOI":"10.1002\/anie.201802979","volume":"57","author":"A Spanopoulou","year":"2018","unstructured":"Spanopoulou, A. et al. Designed Macrocyclic Peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements. Angew. Chem. Int. Ed. 57, 14503\u201314508 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"54919_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/cbic.200800762","volume":"10","author":"R Mishra","year":"2009","unstructured":"Mishra, R., Sellin, D., Radovan, D., Gohlke, A. & Winter, R. Inhibiting islet amyloid polyeptide fibril formation by the red wine component resveratrol. Chem Bio Chem 10, 445\u2013449 (2009).","journal-title":"Chem Bio Chem"},{"key":"54919_CR60","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00249-009-0572-4","volume":"39","author":"L Khemt\u00e9mourian","year":"2010","unstructured":"Khemt\u00e9mourian, L. et al. The role of the disulfide bond in the interaction of islet amyloid polypeptide with membranes. Eur. Biophys. J. 39, 1359\u20131364 (2010).","journal-title":"Eur. Biophys. J."},{"key":"54919_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/09687688.2014.987182","volume":"31","author":"L Caillon","year":"2014","unstructured":"Caillon, L., Duma, L., Lequin, O. & Khemtemourian, L. Cholesterol modulates the interaction of the islet amyloid polypeptide with membranes. Mol Membr biol 31, 239\u2013249 (2014).","journal-title":"Mol Membr biol"},{"key":"54919_CR62","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.bpj.2015.08.033","volume":"109","author":"S Kapoor","year":"2015","unstructured":"Kapoor, S. et al. Effect of the N-Terminal Helix and Nucleotide Loading on the Membrane and Effector Binding of Arl2\/3. Biophys J 109, 1619\u20131629 (2015).","journal-title":"Biophys J"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54919-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:20:26Z","timestamp":1671297626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54919-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54919"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54919-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. and C.G. are shareholders and co-founders of MODAG GmbH. A.L. is partly employed by MODAG. M.S.S., S.R., A.L., J.N., P.P., R.W., L.K. and J.A.K. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19023"}}